BR112014012495A2 - método in vitro, kit, inibidor de egfr e método de tratamento de pacientes afetados com câncer - Google Patents
método in vitro, kit, inibidor de egfr e método de tratamento de pacientes afetados com câncerInfo
- Publication number
- BR112014012495A2 BR112014012495A2 BR112014012495A BR112014012495A BR112014012495A2 BR 112014012495 A2 BR112014012495 A2 BR 112014012495A2 BR 112014012495 A BR112014012495 A BR 112014012495A BR 112014012495 A BR112014012495 A BR 112014012495A BR 112014012495 A2 BR112014012495 A2 BR 112014012495A2
- Authority
- BR
- Brazil
- Prior art keywords
- kit
- treating cancer
- egfr inhibitor
- affected patients
- cancer affected
- Prior art date
Links
- 238000000034 method Methods 0.000 title 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229940121647 egfr inhibitor Drugs 0.000 title 1
- 238000000338 in vitro Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11306568 | 2011-11-25 | ||
| EP12306042 | 2012-08-31 | ||
| PCT/EP2012/073535 WO2013076282A1 (en) | 2011-11-25 | 2012-11-23 | A method for predicting responsiveness to a treatment with an egfr inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014012495A2 true BR112014012495A2 (pt) | 2017-06-06 |
Family
ID=47297187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014012495A BR112014012495A2 (pt) | 2011-11-25 | 2012-11-23 | método in vitro, kit, inibidor de egfr e método de tratamento de pacientes afetados com câncer |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10400284B2 (enExample) |
| EP (1) | EP2783017B1 (enExample) |
| JP (1) | JP6342329B2 (enExample) |
| KR (1) | KR20140104419A (enExample) |
| CN (1) | CN104160038B (enExample) |
| AU (1) | AU2012342397B2 (enExample) |
| BR (1) | BR112014012495A2 (enExample) |
| CA (1) | CA2856594A1 (enExample) |
| MX (1) | MX2014006182A (enExample) |
| WO (1) | WO2013076282A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2931176A1 (en) * | 2013-11-26 | 2015-06-04 | Integragen | A method for predicting responsiveness to a treatment with an egfr inhibitor |
| KR101622454B1 (ko) | 2014-03-04 | 2016-05-18 | 연세대학교 산학협력단 | Egfr 티로신 키나아제 억제제에 대한 항암 치료 반응 예측 마커 |
| WO2015160868A1 (en) * | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | Methods for treating cancer using tor kinase inhibitor combination therapy |
| EP3000895A1 (en) * | 2014-09-26 | 2016-03-30 | Integragen | A method for predicting responsiveness to a treatment with an EGFR inhibitor |
| WO2017014694A1 (en) * | 2015-07-23 | 2017-01-26 | National University Of Singapore | Wbp2 as a co-prognostic factor with her2 for stratification of patients for treatment |
| WO2017187937A1 (ja) * | 2016-04-28 | 2017-11-02 | デンカ株式会社 | 上皮性細胞成長因子受容体阻害剤に対する癌細胞の耐性を判定する方法 |
| CN115943306A (zh) * | 2019-03-29 | 2023-04-07 | 乐天医药生技股份有限公司 | 用于光免疫疗法的方法和相关生物标志物 |
| KR102251864B1 (ko) * | 2019-10-18 | 2021-05-14 | 지니너스 주식회사 | miR-320c를 유효성분으로 포함하는 백금계 항암제에 대한 삼중음성유방암 환자의 약물 반응성 예측용 바이오마커 조성물 |
| CN111798918A (zh) * | 2020-05-28 | 2020-10-20 | 中山大学孙逸仙纪念医院 | 一种免疫治疗疗效预测的血肿瘤突变算法及其构建方法 |
| CN111863159B (zh) * | 2020-06-01 | 2022-02-25 | 中山大学孙逸仙纪念医院 | 一种肿瘤免疫治疗疗效预测的列线图模型的建立方法 |
| JP2025507824A (ja) * | 2022-03-01 | 2025-03-21 | クラウン バイオサイエンス （スーチョウ） インコーポレイテッド | がん患者におけるセツキシマブ感受性を決定するための方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002070751A1 (en) | 2001-03-02 | 2002-09-12 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Pcr method |
| WO2009055343A2 (en) * | 2007-10-22 | 2009-04-30 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
| WO2009080437A1 (en) * | 2007-12-21 | 2009-07-02 | Exiqon A/S | Micro-rna based drug resistance analysis method |
| WO2010015538A2 (en) * | 2008-08-05 | 2010-02-11 | F. Hoffmann-La Roche Ag | Predictive marker for egfr inhibitor treatment |
| EP2419522A4 (en) | 2009-04-17 | 2012-10-31 | Glen Weiss | METHOD AND KITS FOR THE FORECASTING OF THERAPY RESULTS OF TYROSINE CHINESE INHIBITORS |
| AU2010324529A1 (en) * | 2009-11-24 | 2012-07-19 | The University Of Western Australia | Modulation of epidermal growth factor receptor ligands |
| WO2011135459A2 (en) * | 2010-04-29 | 2011-11-03 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy |
-
2012
- 2012-11-23 JP JP2014542865A patent/JP6342329B2/ja not_active Expired - Fee Related
- 2012-11-23 BR BR112014012495A patent/BR112014012495A2/pt active Search and Examination
- 2012-11-23 AU AU2012342397A patent/AU2012342397B2/en not_active Ceased
- 2012-11-23 CA CA2856594A patent/CA2856594A1/en not_active Abandoned
- 2012-11-23 WO PCT/EP2012/073535 patent/WO2013076282A1/en not_active Ceased
- 2012-11-23 EP EP12797814.6A patent/EP2783017B1/en not_active Not-in-force
- 2012-11-23 MX MX2014006182A patent/MX2014006182A/es unknown
- 2012-11-23 CN CN201280067832.4A patent/CN104160038B/zh not_active Expired - Fee Related
- 2012-11-23 US US14/360,311 patent/US10400284B2/en not_active Expired - Fee Related
- 2012-11-23 KR KR1020147014013A patent/KR20140104419A/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP6342329B2 (ja) | 2018-06-13 |
| EP2783017B1 (en) | 2018-12-26 |
| US10400284B2 (en) | 2019-09-03 |
| JP2014533960A (ja) | 2014-12-18 |
| CN104160038A (zh) | 2014-11-19 |
| KR20140104419A (ko) | 2014-08-28 |
| AU2012342397A1 (en) | 2014-06-12 |
| WO2013076282A1 (en) | 2013-05-30 |
| CA2856594A1 (en) | 2013-05-30 |
| AU2012342397B2 (en) | 2018-04-05 |
| US20140370029A1 (en) | 2014-12-18 |
| MX2014006182A (es) | 2014-12-08 |
| EP2783017A1 (en) | 2014-10-01 |
| CN104160038B (zh) | 2018-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014012495A2 (pt) | método in vitro, kit, inibidor de egfr e método de tratamento de pacientes afetados com câncer | |
| IL286921A (en) | Pertuzumab and trastuzumab for use in therapy | |
| HUE036583T2 (hu) | Notch jelzõ folyamat inhibitorai és alkalmazásuk rákok kezelésében | |
| SMT201600430B (it) | Inibitori di chinasi e loro uso nel trattamento del cancro | |
| BR112014007603A2 (pt) | métodos de tratamento do câncer | |
| PL2768493T3 (pl) | Fitokannabinoidy do stosowania w leczeniu raka piersi | |
| BRPI1015179A2 (pt) | biomarcadores e métodos para a determinação de eficácia de anticorpos anti-egfr em terapia de câncer | |
| BR112014001440A2 (pt) | novas composições e métodos para o tratamento de câncer de próstata | |
| BR112014006419A2 (pt) | métodos para tratar um paciente com câncer, kit e artigo | |
| PL2552438T3 (pl) | Sposoby leczenia raka wątrobowokomórkowego | |
| HUE040445T2 (hu) | Antiszensz molekulák és eljárások betegségek kezelésére | |
| PL2739153T3 (pl) | Leczenie raka sutka | |
| DK2473510T3 (da) | Jak-2-hæmmere og anvendelse heraf til behandling af myeloproliferativesygdomme og cancer | |
| EP2547292A4 (en) | INTERVERTEBRAL IMPLANTS AND SYSTEMS AND METHODS FOR IMPLANTATION OF A GRAFT | |
| PT2434891T (pt) | Métodos para tratamento de cancro e afeções não neoplásicas | |
| BR112014009755A2 (pt) | tratamento de câncer com inibidores de quinase tor | |
| IL232256A0 (en) | Novel purine derivatives and their use in the treatment of disease | |
| BR112013007678A2 (pt) | método para tratamento de doenças alérgicas | |
| BR112013012485A2 (pt) | método de tratamento com inibidor braf | |
| IL220788A (en) | Factors associated with cancer treatment and method of preparation | |
| BR112014004937A2 (pt) | método para tratar e/ou prevenir um câncer dependente de ligante de ahr natural e inibidor de ahr | |
| PT2528946T (pt) | Métodos de tratamento de doenças autoimunes com antagonistas de dll4 | |
| PT2678675T (pt) | Métodos de deteção de aneuploidia em embriões humanos | |
| BR112014001973A2 (pt) | composto e método de tratamento do câncer em um sujeito | |
| IL225262A0 (en) | Methods and compositions for treating lung cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08H | Application fees: decision cancelled [chapter 8.8 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 8.6 NA RPI NO 2541 DE 17/09/2019 POR TER SIDO INDEVIDA. |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |